SE378109B - - Google Patents

Info

Publication number
SE378109B
SE378109B SE7206644A SE664472A SE378109B SE 378109 B SE378109 B SE 378109B SE 7206644 A SE7206644 A SE 7206644A SE 664472 A SE664472 A SE 664472A SE 378109 B SE378109 B SE 378109B
Authority
SE
Sweden
Application number
SE7206644A
Inventor
R L Brattsand
K G Claeson
Af Ekenstam B Thuresson
B A Thalen
Original Assignee
Bofors Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20269234&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE378109(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to SE7206644A priority Critical patent/SE378109B/xx
Application filed by Bofors Ab filed Critical Bofors Ab
Priority to IL42155A priority patent/IL42155A/en
Priority to ZA732955A priority patent/ZA732955B/xx
Priority to AU55253/73A priority patent/AU487812B2/en
Priority to DE2323215A priority patent/DE2323215C3/de
Priority to GB2219473A priority patent/GB1429922A/en
Priority to CY1013A priority patent/CY1013A/xx
Priority to ES414673A priority patent/ES414673A1/es
Priority to US360051A priority patent/US3929768A/en
Priority to FI731542A priority patent/FI50631C/fi
Priority to YU1291/73A priority patent/YU35896B/xx
Priority to CH699973A priority patent/CH595400A5/xx
Priority to DK277273AA priority patent/DK134783B/da
Priority to DD170888A priority patent/DD104295A5/xx
Priority to BE131270A priority patent/BE799727A/xx
Priority to CA171,785A priority patent/CA1002938A/en
Priority to NO2059/73A priority patent/NO139640C/no
Priority to HUBO1438A priority patent/HU166680B/hu
Priority to PL1973162650A priority patent/PL87765B1/pl
Priority to SU1923451A priority patent/SU470954A3/ru
Priority to FR7318125A priority patent/FR2185405B1/fr
Priority to AT436573A priority patent/AT328630B/de
Priority to CS3590A priority patent/CS178129B2/cs
Priority to NLAANVRAGE7306978,A priority patent/NL177493C/xx
Priority to JP5623373A priority patent/JPS5521760B2/ja
Publication of SE378109B publication Critical patent/SE378109B/xx
Priority to US05/629,389 priority patent/US3983233A/en
Priority to KE2970A priority patent/KE2970A/xx
Priority to HK491/79A priority patent/HK49179A/xx
Priority to NL930025C priority patent/NL930025I1/nl
Priority to NO1994013C priority patent/NO1994013I1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
SE7206644A 1972-05-19 1972-05-19 SE378109B (zh)

Priority Applications (30)

Application Number Priority Date Filing Date Title
SE7206644A SE378109B (zh) 1972-05-19 1972-05-19
IL42155A IL42155A (en) 1972-05-19 1973-05-01 16alpha,17alpha-alkylidenedioxy-11beta,21-dihydroxy-pregna-1,4-diene-3,20-diones their manufacture and preparations containing same
ZA732955A ZA732955B (en) 1972-05-19 1973-05-01 New steroids,processes for their manufacture and preparations containing same
AU55253/73A AU487812B2 (en) 1972-05-19 1973-05-04 New Steroids, processes for their manufacture and preparations containing same
DE2323215A DE2323215C3 (de) 1972-05-19 1973-05-09 Pregna-l,4-dien-ll-ol-3,20-dione, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel
GB2219473A GB1429922A (en) 1972-05-19 1973-05-09 Steroid acetals processes for their manufacture and preparations containing them
CY1013A CY1013A (en) 1972-05-19 1973-05-09 Steroid acetals, processes for their manufacture and preparations containing them
ES414673A ES414673A1 (es) 1972-05-19 1973-05-11 Procedimiento para preparar esteroides.
FI731542A FI50631C (fi) 1972-05-19 1973-05-14 Menetelmä pregnadieenijohdannaisten valmistamiseksi.
US360051A US3929768A (en) 1972-05-19 1973-05-14 Steroids, processes for their manufacture and preparations containing same
YU1291/73A YU35896B (en) 1972-05-19 1973-05-16 Process for obtaining steroids
CH699973A CH595400A5 (zh) 1972-05-19 1973-05-16
DK277273AA DK134783B (da) 1972-05-19 1973-05-17 Analogifremgangsmåde til fremstilling af 16alfa,17alfa-alkylidendioxypregna-1,4-dien-11beta,21-diol-3,20-dioner.
DD170888A DD104295A5 (zh) 1972-05-19 1973-05-17
CA171,785A CA1002938A (en) 1972-05-19 1973-05-18 Steroids, processes for their manufacture and preparations containing same
BE131270A BE799727A (fr) 1972-05-19 1973-05-18 Nouveaux steroides physiologiquement actifs, et procede pour leur preparation.
NLAANVRAGE7306978,A NL177493C (nl) 1972-05-19 1973-05-18 Werkwijze voor de bereiding van steroiden en werkwijze ter bereiding van een farmaceutisch preparaat tegen ontstekingen.
NO2059/73A NO139640C (no) 1972-05-19 1973-05-18 Analogifremgangsmaate for fremstilling av fysiologisk virksomme 16alfa,17alfa-alkylidendioksypregna-1,4-dien-3,20-dioner
HUBO1438A HU166680B (zh) 1972-05-19 1973-05-18
PL1973162650A PL87765B1 (zh) 1972-05-19 1973-05-18
SU1923451A SU470954A3 (ru) 1972-05-19 1973-05-18 Способ получени производных кортикостероидов
FR7318125A FR2185405B1 (zh) 1972-05-19 1973-05-18
AT436573A AT328630B (de) 1972-05-19 1973-05-18 Verfahren zur herstellung neuer steroide
CS3590A CS178129B2 (zh) 1972-05-19 1973-05-18
JP5623373A JPS5521760B2 (zh) 1972-05-19 1973-05-19
US05/629,389 US3983233A (en) 1972-05-19 1975-11-06 Compositions and method of treating with stereoisomeric mixtures of 2-unsymmetrical 16,17-methylenedioxy steroids
KE2970A KE2970A (en) 1972-05-19 1979-06-20 New steriod acetals, process for their manufacture and preparations containing them
HK491/79A HK49179A (en) 1972-05-19 1979-07-19 New steroid acetals, processes for their manufacture and preparations containing them
NL930025C NL930025I1 (nl) 1972-05-19 1993-04-13 Werkwijze voor de bereiding van steroïden en werkwijze ter bereiding van een farmaceutisch preparaattegen ontstekingen
NO1994013C NO1994013I1 (no) 1972-05-19 1994-08-31 Budenosid/ 16¿, 17¿-alkyldendioksypregna-1,4-dien-3,20-dioner

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7206644A SE378109B (zh) 1972-05-19 1972-05-19

Publications (1)

Publication Number Publication Date
SE378109B true SE378109B (zh) 1975-08-18

Family

ID=20269234

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7206644A SE378109B (zh) 1972-05-19 1972-05-19

Country Status (26)

Country Link
US (2) US3929768A (zh)
JP (1) JPS5521760B2 (zh)
AT (1) AT328630B (zh)
BE (1) BE799727A (zh)
CA (1) CA1002938A (zh)
CH (1) CH595400A5 (zh)
CS (1) CS178129B2 (zh)
CY (1) CY1013A (zh)
DD (1) DD104295A5 (zh)
DE (1) DE2323215C3 (zh)
DK (1) DK134783B (zh)
ES (1) ES414673A1 (zh)
FI (1) FI50631C (zh)
FR (1) FR2185405B1 (zh)
GB (1) GB1429922A (zh)
HK (1) HK49179A (zh)
HU (1) HU166680B (zh)
IL (1) IL42155A (zh)
KE (1) KE2970A (zh)
NL (2) NL177493C (zh)
NO (2) NO139640C (zh)
PL (1) PL87765B1 (zh)
SE (1) SE378109B (zh)
SU (1) SU470954A3 (zh)
YU (1) YU35896B (zh)
ZA (1) ZA732955B (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170642A2 (en) * 1984-07-30 1986-02-05 Aktiebolaget Draco Liposomes containing steroid esters
EP0197018A1 (en) * 1985-04-04 1986-10-08 Aktiebolaget Draco 16,17-Acetal-substituted androstane-17-beta-carboxylic-acid esters, process for their preparation and pharmaceutical compound containing them
EP0232690A1 (en) * 1985-12-19 1987-08-19 Aktiebolaget Draco Novel 16,17-acetalsubstituted pregnane-21-oic acid derivatives, process for the preparation thereof and pharmaceutical preparation containing them
US5215979A (en) * 1985-12-19 1993-06-01 Aktiebolaget Draco 16,17-acetalsubstituted pregnane 21-oic acid derivatives

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8004580L (sv) * 1980-06-19 1981-12-20 Draco Ab Farmaceutisk beredning
SE8008524L (sv) * 1980-12-04 1982-06-05 Draco Ab 4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
IT1196142B (it) * 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
SE8604059D0 (sv) * 1986-09-25 1986-09-25 Astra Pharma Prod A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
LV5274A3 (lv) * 1988-02-29 1993-10-10 Richter Gedeon Vegyeszet 22(R,S)-11 beta,21-dihidroksi-16 alpha,17-butilidenbisoksipregna-1,4-dien-3,20-diona iegusanas panemiens
HU203769B (en) * 1989-03-09 1991-09-30 Richter Gedeon Vegyeszet Process for producing new steroide derivatives and pharmaceutical compositions containing them
SE8903219D0 (sv) * 1989-10-02 1989-10-02 Astra Ab Process for the manufacture of budesonide
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
US5643602A (en) * 1989-11-22 1997-07-01 Astra Aktiebolag Oral composition for the treatment of inflammatory bowel disease
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
SE9100342D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroid esters
SE9100341D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroids
US5888995A (en) * 1991-02-04 1999-03-30 Astra Aktiebolag Steroid esters
IE67345B1 (en) * 1991-03-12 1996-03-20 Akzo Nv Low dose dry pharmaceutical preparations
FR2675146A1 (fr) * 1991-04-10 1992-10-16 Roussel Uclaf Nouveaux derives sterouides de la pregna-1,4-diene-3,20-dione, leur preparation, leur application a la preparation de derives 16,17-methylene dioxy substitues et nouveaux intermediaires.
MD24B1 (ro) * 1991-07-09 1994-05-31 Parfumerii Si Cosmetice Vioric Compozitie de substante odorante
LT3695B (en) 1991-11-18 1996-02-26 Dineika Raimundas Arnas Folded roof
AU673660C (en) * 1991-12-18 2002-07-25 Astrazeneca Ab New combination of formoterol and budesonide
IL108167A0 (en) * 1992-12-24 1994-04-12 Rhone Poulenc Rorer Ltd Steroids, their preparation and pharmaceutical compositions containing them
WO1994015947A1 (en) * 1993-01-08 1994-07-21 Astra Aktiebolag Novel colon- or ileum-specific steroid derivatives
GB9423919D0 (en) * 1994-11-26 1995-01-11 Rhone Poulenc Rorer Ltd Chemical process
US6166024A (en) * 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
FR2756739B1 (fr) * 1996-12-05 2000-04-28 Astra Ab Nouvelle formulation de budesonide
IT1291288B1 (it) 1997-04-30 1999-01-07 Farmabios Srl Processo per la preparazione di 16,17 acetali di derivati pregnanici con controllo della distribuzione epimerica al c-22.
DE29717252U1 (de) * 1997-09-26 1998-02-19 Falk Pharma Gmbh Arzneimittelkit aus einem Budesonid-haltigen und einem Ursodesoxycholsäure-haltigen Arzneimittel zur Behandlung von cholestatischen Lebererkrankungen
US6266556B1 (en) 1998-04-27 2001-07-24 Beth Israel Deaconess Medical Center, Inc. Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
AU777770C (en) 1999-05-04 2005-11-10 Strakan International Limited Androgen glycosides and androgenic activity thereof
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
GB0009613D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
WO2004033478A2 (en) * 2002-10-08 2004-04-22 Sepracor Inc. Fatty acid modified forms of glucocorticoids and their use as anti-inflammatory
WO2004091596A2 (en) * 2003-04-18 2004-10-28 Pharmacia & Upjohn Company Llc Combination therapies for chronic obstructive pulmonary disease (copd)
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
AU2004268847A1 (en) * 2003-08-29 2005-03-10 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
WO2005051931A2 (en) * 2003-11-26 2005-06-09 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
WO2005100356A1 (en) 2004-04-09 2005-10-27 Merck & Co., Inc. Inhibitors of akt activity
ES2382814T3 (es) 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
TW200744612A (en) * 2005-08-26 2007-12-16 Astrazeneca Ab New combination
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
EP1948164A1 (en) 2005-10-19 2008-07-30 Ranbaxy Laboratories, Ltd. Pharmaceutical compositions of muscarinic receptor antagonists
BRPI0617673C1 (pt) * 2005-10-19 2012-05-22 Ranbaxy Lab Ltd composições de inibidores de fosfodiesterase do tipo iv
US20070135398A1 (en) * 2005-11-02 2007-06-14 Pierluigi Rossetto Process for the preparation of ciclesonide
AR059216A1 (es) 2006-01-27 2008-03-19 Sun Pharmaceutical Ind Ltd 11b-hidroxiandrosta-4-eno-3-onas
US20070232578A1 (en) * 2006-02-15 2007-10-04 Pierluigi Rossetto Crystalline forms of ciclesonide
ES2296516B1 (es) * 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
AP2690A (en) 2006-08-22 2013-07-15 Ranbaxy Laboratoiries Ltd Matrix metalloproteinase inhibitors
AU2007298549A1 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
US20100029728A1 (en) * 2006-09-22 2010-02-04 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
ES2302447B1 (es) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
PT2099442E (pt) 2006-12-26 2015-02-10 Pharmacyclics Inc Métodos de utilização de inibidores de histona desacetilase e monitorização de biomarcadores em terapia de combinação
BRPI0806245B1 (pt) 2007-01-10 2022-01-25 Msd Italia S.R.L. Compostos de fórmula i e seus usos
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
EP1958639A1 (en) 2007-02-14 2008-08-20 Polichem S.A. Use of chitosans for the treatment of nail inflammatory diseases
US10201490B2 (en) 2007-02-14 2019-02-12 Polichem Sa Use of chitosans for the treatment of nail inflammatory diseases
US20080207659A1 (en) * 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
EP2124943A1 (en) * 2007-03-14 2009-12-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b]pyridine derivatives as phosphodiesterase inhibitors
MX2009009793A (es) 2007-03-14 2009-10-16 Ranbaxy Lab Ltd Derivados de pirazolo (3,4-b) piridina como inhibidores de fosfodiesterasa.
EP2170076B1 (en) 2007-06-27 2016-05-18 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US20090082319A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched budesonide
WO2009045539A2 (en) 2007-10-05 2009-04-09 Nektar Therapeutics Al, Corporation Oligomer-corticosteroid conjugates
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2096105A1 (en) * 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
EP2262823B1 (en) * 2008-03-13 2013-01-23 Farmabios S.p.A. Process for the preparation of pregnane derivatives
ITMI20080645A1 (it) 2008-04-11 2009-10-12 Ind Chimica Srl Procedimento per la preparazione di budesonide
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
CN101279997B (zh) * 2008-05-29 2011-08-24 鲁南制药集团股份有限公司 布***的一种制备方法
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
GB0900484D0 (en) 2009-01-13 2009-02-11 Angeletti P Ist Richerche Bio Therapeutic agent
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
CN107412212B (zh) 2009-05-29 2021-01-22 珍珠治疗公司 经肺递送长效毒蕈碱拮抗剂及长效β2肾上腺素能受体激动剂的组合物及相关方法与***
GB0916608D0 (en) 2009-09-22 2009-11-04 Angeletti P Ist Richerche Bio Therapeutic compounds
DK3403654T3 (da) 2009-10-01 2019-08-26 Adare Dev I L P Oralt administrerede kortikosteroidsammensætninger
WO2011046771A1 (en) 2009-10-14 2011-04-21 Schering Corporation SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
WO2011093812A2 (en) 2010-01-28 2011-08-04 Mahmut Bilgic Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form
WO2011097594A2 (en) 2010-02-08 2011-08-11 Kinagen, Inc. Therapeutic methods and compositions involving allosteric kinase inhibition
CN101863952B (zh) * 2010-04-30 2013-04-17 湖北葛店人福药业有限责任公司 布***的制备方法
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
WO2012024170A2 (en) 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
JP2014514321A (ja) 2011-04-21 2014-06-19 メルク・シャープ・アンド・ドーム・コーポレーション インスリン様増殖因子１受容体阻害剤
SG2014014419A (en) 2011-09-13 2014-07-30 Pharmacyclics Inc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
WO2013109214A1 (en) 2012-01-16 2013-07-25 Mahmut Bilgic Process for the preparation of dry powder formulations
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
CN103421075B (zh) * 2012-05-16 2017-07-28 上海特化医药科技有限公司 孕烷衍生物16,17‑缩醛(酮)的制备方法
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
WO2014007772A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising glucose anhydrous
WO2014007781A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions
WO2014007770A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising corticosteroid and sorbitol
NZ704799A (en) 2012-08-24 2018-06-29 Univ Texas Heterocyclic modulators of hif activity for treatment of disease
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
MX363243B (es) 2012-11-28 2019-03-14 Merck Sharp & Dohme Composiciones para tratar cáncer y usos de dichas composiciones.
RU2690663C2 (ru) 2012-12-20 2019-06-05 Мерк Шарп И Доум Корп. Замещенные имидазопиридины в качестве ингибиторов hdm2
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
RU2696582C2 (ru) 2013-03-15 2019-08-05 Перл Терапьютикс, Инк. Способы и системы кондиционирования дисперсных кристаллических материалов
KR20160013134A (ko) 2013-05-22 2016-02-03 펄 테라퓨틱스 인코포레이티드 3 개 이상의 활성제의 호흡기 전달을 위한 조성물, 방법 및 시스템
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
CA2936741C (en) 2014-10-31 2018-11-06 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10233210B2 (en) 2015-01-30 2019-03-19 Coral Drugs Pvt. Ltd. Process for preparation of glucocorticoid steroids
US11066396B2 (en) 2016-06-23 2021-07-20 Merck Sharp & Dohme Corp. 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
WO2018089373A2 (en) 2016-11-08 2018-05-17 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
MX2019013690A (es) 2017-05-18 2020-01-27 Regeneron Pharma Conjugados de farmaco-proteina con ciclodextrina.
CA3098453A1 (en) 2018-05-09 2019-11-14 Regeneron Pharmaceuticals, Inc. Anti-msr1 antibodies and methods of use thereof
EP3833668A4 (en) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
AU2020408148A1 (en) 2019-12-17 2022-06-16 Merck Sharp & Dohme Llc PRMT5 inhibitors
IL309888A (en) 2021-07-09 2024-03-01 Astrazeneca Pharmaceuticals Lp Aerosol drug delivery compounds, methods and systems
WO2023119093A1 (en) 2021-12-20 2023-06-29 Astrazeneca Ab Compositions, methods and systems for aerosol drug delivery
WO2024049931A1 (en) 2022-09-02 2024-03-07 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3126375A (en) * 1964-03-24 Chioacyl
US3133940A (en) * 1956-04-10 1964-05-19 Glaxo Group Ltd Process for the separation of delta-1, 4-3-keto steroid compounds from mixtures thereof with other 3-keto steroids
US2990401A (en) * 1958-06-18 1961-06-27 American Cyanamid Co 11-substituted 16alpha, 17alpha-substituted methylenedioxy steroids
US3197469A (en) * 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US3048581A (en) * 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3128238A (en) * 1962-09-14 1964-04-07 Lilly Co Eli delta1-dehydrogenation of steroids by fermentation with actinoplanaceae
JPS4843910A (zh) * 1971-10-08 1973-06-25

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170642A2 (en) * 1984-07-30 1986-02-05 Aktiebolaget Draco Liposomes containing steroid esters
EP0170642A3 (en) * 1984-07-30 1986-10-29 Aktiebolaget Draco Liposomes containing steroid esters
US4693999A (en) * 1984-07-30 1987-09-15 Aktiebolaget Draco Liposomes containing steroid esters
EP0197018A1 (en) * 1985-04-04 1986-10-08 Aktiebolaget Draco 16,17-Acetal-substituted androstane-17-beta-carboxylic-acid esters, process for their preparation and pharmaceutical compound containing them
EP0355859A1 (en) * 1985-04-04 1990-02-28 Aktiebolaget Draco Process for the preparation of intermediates for 11-beta,16-alpha,17-alpha,21-tetrahydroxypregna-3,20-dione 16-alpha,17-alpha-acetals and 21-esters thereof
US4950659A (en) * 1985-04-04 1990-08-21 Aktiebolaget Draco 16,17-acetalsubstituted androstane-17β-carboxylic acid esters prossessing high binding affinity to the glucocorticosteroid receptor
EP0232690A1 (en) * 1985-12-19 1987-08-19 Aktiebolaget Draco Novel 16,17-acetalsubstituted pregnane-21-oic acid derivatives, process for the preparation thereof and pharmaceutical preparation containing them
US5215979A (en) * 1985-12-19 1993-06-01 Aktiebolaget Draco 16,17-acetalsubstituted pregnane 21-oic acid derivatives

Also Published As

Publication number Publication date
DK134783B (da) 1977-01-17
FI50631C (fi) 1976-05-10
AU5525373A (en) 1974-11-07
NO1994013I1 (no) 1994-08-31
DE2323215C3 (de) 1978-03-30
JPS5521760B2 (zh) 1980-06-12
NL177493C (nl) 1985-10-01
BE799727A (fr) 1973-09-17
AT328630B (de) 1976-03-25
PL87765B1 (zh) 1976-07-31
CS178129B2 (zh) 1977-08-31
CA1002938A (en) 1977-01-04
IL42155A0 (en) 1973-07-30
US3983233A (en) 1976-09-28
ATA436573A (de) 1975-06-15
DD104295A5 (zh) 1974-03-05
DE2323215B2 (de) 1977-08-11
NL930025I1 (nl) 1993-06-01
ZA732955B (en) 1974-04-24
FR2185405A1 (zh) 1974-01-04
FI50631B (zh) 1976-02-02
SU470954A3 (ru) 1975-05-15
HK49179A (en) 1979-07-27
NO139640B (no) 1979-01-08
IL42155A (en) 1977-06-30
HU166680B (zh) 1975-05-28
FR2185405B1 (zh) 1976-12-31
US3929768A (en) 1975-12-30
YU129173A (en) 1981-02-28
CH595400A5 (zh) 1978-02-15
YU35896B (en) 1981-08-31
DE2323215A1 (de) 1973-11-29
GB1429922A (en) 1976-03-31
KE2970A (en) 1979-07-20
NO139640C (no) 1979-04-18
NL7306978A (zh) 1973-11-21
ES414673A1 (es) 1976-07-01
CY1013A (en) 1979-11-23
DK134783C (zh) 1977-06-06
JPS4941378A (zh) 1974-04-18
NL177493B (nl) 1985-05-01

Similar Documents

Publication Publication Date Title
FI50631B (zh)
FR2173089B1 (zh)
JPS48103758U (zh)
AU465371B2 (zh)
JPS494545U (zh)
AU465442B2 (zh)
JPS49103452U (zh)
JPS4950363A (zh)
JPS4954873A (zh)
CH580296B5 (zh)
CH579419A5 (zh)
CH578001A5 (zh)
CH578053A5 (zh)
CH576420A5 (zh)
CH577995A5 (zh)
BE781579R (zh)
BG17408A1 (zh)
CH576214A5 (zh)
CH577264A5 (zh)
CH578761B5 (zh)
CH579531A5 (zh)
CH576157A5 (zh)
CH576425A5 (zh)
CH576979A5 (zh)
CH577958A5 (zh)